Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Completed · Phase 1/Phase 2

Conditions studied: Myelodysplastic Syndrome

In brief

Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, patients with intermediate- or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety of the study treatment. Safety assessments will include echocardiograms, electrocardiograms and routine safety laboratory studies (hematology and serum chemistry). In addition, clinical response to treatment will be monitored using bone marrow aspirates or biopsies, and other routine methods.

Key facts

Study ID
NCT02018926
Run by
Mirati Therapeutics Inc.
People needed
18
Starts
2013-12-01
Expected to finish
2015-09-01
Last updated by the study team
2017-09-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.